However, large-scale cardiovascular (CV) outcomes trials (CVOTs) with DPP-4 inhibitors demonstrated CV safety but did not show a reduction in CV events
Patents cover coformulations with SGLT2 inhibitors, thyroid hormone receptor beta agonists, and other metabolic targets [25, 26], mirroring the scientific literature's growing focus on GLP-1's effects across MASH, cardiovascular disease, and other obesity-related conditions [27, 28]
Early CVOTs on GLP-1RAs, such as the LEADER, Harmony Outcomes, REWIND, and SUSTAIN-6 trials, focused on patients with T2DM and demonstrated the cardioprotective effects of these agents, including liraglutide, albiglutide, dulaglutide, and semaglutide.[811] The potential cardiovascular benefits of GLP-1RAs in patients without diabetes remain an active area of research
use is more start-and-stop than most people assumed. Using Cox proportional hazards models, they also took sociodemographic, clinical and provider-level predictors into consideration
Focus on form
Batsis is particularly concerned about the risks of sarcopenia, which can be a problem for people with excess fat as well as those who are thin and may appear frailer